
    
      This study is a single-center, unblinded, non-randomized clinical trial for adjunctive
      prophylactic treatment of episodic migraine headache using neuromodulation device developed
      by Scion NeuroStim, LLC (SNS). The investigational use of the device for episodic migraine
      headache has been reviewed by the FDA and is classified as NSR (non-significant risk).
    
  